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MYOBLAST 
TRANSPLANTATION 
IN THE PORCINE MODEL: 
A POTENTIAL TECHNIQUE 
FOR MYOCARDIAL REPAIR 
The use of transgenic cells transplanted in syngeneic rodents has shown 
modest success, but allogeneic and xenogeneic transplants have not been 
uniformly successful. To assess the feasibility of xenogeneic and allogeneic 
myoblast transplantation, we subjected seven adult swine to transplanta- 
tion of murine atrial tumor cells (xenogeneic), neonatal porcine myocytes 
(allogeneic), and human fetal cardiomyocytes into the left ventricular wall. 
After general anesthesia, isolated cells were injected along the anterior and 
posterior walls of the porcine left ventricle. All the animals were immuno- 
suppressed and observed for 1 month after injection, at which time they 
were killed and analyzed. This report will present results primarily 
concerned with the success of human cell transfers. In all injected sites 
examined, the transplanted cells thrived within the host myocardium with 
no significant rejection. Transplant cells formed close associations with 
host myocytes that resembled nascent intercalated disks on electron 
microscopy. These cells also contained myofibrils and other cell architec- 
ture resembling the transplanted cell lines. Additionally, these cells ap- 
peared to produce an angiogenic influence resulting in the proliferation of 
the surrounding microvasculature. We believe that these findings indicate 
successful xenogeneic and allogeneic myoblast cell transplantation in a 
large animal model. These experiments et the stage for future studies to 
assess the ability of these cells to form a syncytium, contract, and 
potentially repair failed myocardium. (J THORAC CARDIOVASC SURG 1995; 
110:1442-8) 
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T he relative shortage of donor hearts continues to fuel the fforts to establish other methods to 
manage heart failure. Many have expanded the 
criteria for acceptability of donor hearts and 
continue to experiment clinically with ventricular 
assist devices, skeletal cardiomyoplasty, and even 
total artificial hearts. Simultaneously, research 
has continued in the arena of cellular transplan- 
tation. 
Parallel research along this line, with satellite cells 
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in skeletal muscle, has been previously reported. 1 
These cells do not fuse with others or synthesize 
contractile proteins and are left wedged between the 
plasma and base membranes of the muscle fiber. 
They play a primary role in the regeneration of 
skeletal muscle after injury. 
Unlike skeletal muscle, cardiac muscle differen- 
tiation is unusual in that it occurs early in fetal life 
in the dividing cell. The reason is that the heart is 
one of the first organs to form during develop- 
ment and, as such, gains function while it is still 
growing by cell division. Because cardiac muscle 
cells continue to divide as they are differentiat- 
ing, 2 it may be that they have two separate 
developmental programs for terminal differentia- 
tion. Ongoing research is attempting to identify 
the genes that control cardiac myocyte differenti- 
ation and the myocyte cell cycle. This report 
summarizes the results of our pilot studies with 
experimental cardiomyoblast tr nsplantation. 
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Methods 
Preparation of adult rat ventrieular cardiomyocytes. 
Ventricular cardiomyocytes were isolated from adult fe- 
male rats (200 to 300 gm) by means of the protocols of 
Claycomb and Palazzo 3and modified after Claycomb and 
Lanson. 4Rats were anesthetized, and their beating hearts 
were removed and placed into cold Joklik's medium. 
Hearts were then attached to a short Friedrick's con- 
denser by a three-way stopcock and perfused retrogradely 
through the aorta with enzyme-free Joklik's medium. This 
was followed immediately by retrograde perfusion with 
Joklik's medium containing type II collagenase in a 1 
mg/ml concentration. All solutions were maintained at 
37 ° C and gassed with a 0.8 mm filtered mixture of 95% 
oxygen and 5% carbon dioxide. Once softened, the hearts 
were removed, minced, and subjected to gentle digestion 
in fresh collagenase by stirring a heated rotating shaker 
bath. Every 10 minutes, cells were collected, washed in 
serum-free Joklik's medium, and pooled. 
Preparation of AT-1 cells. AT-1 cells were isolated 
from subcutaneous atrial tumors by means of techniques 
previously published. 5' 6 The tumors were excised from 
their subcutaneous location and rinsed in phosphate- 
buffered saline solution. The tumors were minced in 
phosphate-buffered saline solution, transferred to a 
trypsinizing flask containing 0.125% trypsin, and treated 
as described earlier for rat ventricles. Cells were counted 
and pooled. 
Preparation of isolated fetal human eardiomyocytes. 
Fetal human hearts (14 to 18 weeks of gestation) were 
obtained from Advanced Bioscience Resources, Inc. 
(Almeda, Calif.). The hearts were procured immediately 
after abortions, rinsed in saline solution, placed in ice- 
cold, sterile, high-glucose Dulbecco's modified Eagle's 
medium, packed in wet ice, and shipped by overnight 
carrier. Ventricular and atrial heart muscle cells were 
isolated by the same procedures and with the same 
apparatus used previously to isolate cardiac myocytes 
from adult rats and monkeys. 7~I° These procedures are 
easily adaptable to fetal human hearts because at this 
developmental ge they are approximately the same size 
as hearts from adult rats and squirrel monkeys. Under 
aseptic conditions, the hearts were perfused in a retro- 
grade manner via the aorta with 1 mg of collagenase per 
milliliter of Joklik's medium followed by sequential diges- 
tion of minced pieces of ventricular or atrial tissue in fresh 
enzyme solution. Dissociated cells were washed several 
times in J0klik's nledium for purification and injected 
within several hours after isolation. 
Injection of cardiomyocytes and eardiomyblasts into 
test animals. Seven adult swine were anesthetized with 
ketamine and barbiturates, intubated, and their lungs 
ventilated with isoflurane via a pressure-controlled r spi- 
rator. Venous access was accomplished with a Port-A- 
Cath catheter (Pharmacia Biosystems, Piscataway, N.J.) 
and bretylium was injected as a bolus at a rate of 5 mg/kg 
followed by a constant infusion to prevent ventricular 
arrhythmia s. 
Using aseptic technique, we made a midline sternotomy 
and created a pericardial well. We then injected 10 bd of 
cells in solution (approximately 104 cardiomyoblasts in 
Joklik's medium) into the ventricular wall using a 26- 
gauge micropuncture needle connected to a tuberculin 
syringe. Controlled injections were performed with 10 ml 
of Joklik's medium only. The midline sternotomy was 
closed and the pericardial and thoracic spaces were evac- 
uated of residual air. 
All animals were given cyclosporine (Sandimune, San- 
doz Pharmaceuticals, E. Hannover, N.J.) at a rate of 15 
mg/kg twice a day by intravenous bolus to maintain 
therapeutic yclosporine levels. Animals were killed 1 
month after injection and their hearts were examined by 
light and transmission electron microscopes. 
One month after cellular implantation, all animals were 
killed and the hearts excised and prepared for examina- 
tion by light and electron microscopy as follows. 
Microscopy 
Microscopic examination of whole tissue. Isolated hearts 
were perfused through the coronary tree with a phos- 
phate-buffered 4% paraformaldehyde-1% glutaraldehyde 
fixative. Excised whole hearts were fixed an additional 7
days in 4.0% glutaraldehyde and 0.1 mol/L sodium caco- 
@late. Injection sites were located by identifying Prolene 
sutures (Ethicon, Inc., Somerville, N.J.) implanted at the 
initial operation. Excised areas were cut into 1 cm squares 
and then rinsed for an additional week in 0.1 mol/L 
sodium cacodylate buffer with frequent changes of buffer. 
Blocks were further sectioned into smaller samples for 
examination with both electron and light microscopes. 
Electron microscopy. Tissue samples were postfixed in 
1.0% osmium tetroxide and 0.1 mol/L sodium cacodylate, 
stained en bloc with 0.5% aqueous uranyl acetate, dehy- 
drated in acetone, and infiltrated and embedded in Poly- 
bed 812 fixative (Polysciences, Inc., Warrington, Pa.). 
Thin sections were examined with a JEOL 1210 transmis- 
sion electron microscope (JEOL USA, Inc., Peabody, 
Mass.), at 60 kV. Images were obtained on Kodak 4489 
EM film (Eastman Kodak Company, Rochester, N.Y.). 
Standard light histologic studies. Tissue blocks were 
prepared for light microscopy, embedded in paraffin, 
sectioned, and stained with hematoxylin and eosin. Sec- 
tions were examined with a Leitz Dialux 20 microscope 
(Wild Microscopes, Div. of Leica, Inc., Rockleigh, N.J.). 
Images were captured on Kodak T-Max 100 film at 
various levels of magnification. 
All animals received humane care in compliance with 
the "Principles of Laboratory Animal Care" formulated 
by the National Society for Medical Research and the 
"Guide for the Care and Use of Laboratory Animals" 
prepared by the Institute of Laboratory Animal Resources 
and published by The National Institutes of Health (NIH 
Publication #86-23, revised 1985) and in conjunction with 
the Ochsner Medical Institutions Research and Education 
Division Animal Care Committee. 
Results 
Al l  seven laboratory animals received injections 
of cells without per ioperat ive compl icat ion and sur- 
vived without morbidity until being put to death for 
harvesting. There was no increase in creatine kinase 
MB isoenzyme fraction within 24 hours after injec- 
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Fig. 1. Injected fetal human atrial cardiomyocytes (HA) are visible as basophilic regions in the left 
ventricle of the adult pig host (PV). Note the absence of any connective tissue capsule (arrow) and 
lymphocytes. (Hematoxylin and eosin stain; final magnification x 160.) 
Fig. 2. Injected fetal human atrial cardiomyocytes (HA) also induce what appear to be nascent blood 
vessels both within the graft and in the interface between graft and host (*). PV, Pig ventricle. Fig. 2 is a 
higher magnification view of the area demonstrated in Fig. 1. (Hematoxylin and eosin stain; final 
magnification x400.) 
tion, suggesting that there was no significant myo- 
cardial injury from the cellular implantation. 
Histologic examination of the excised hearts 
containing grafted human cardiomyocytes demon- 
strated no evidence of overt rejection. The cells 
seemed to align with the native myocytes and most 
significantly have exerted an angiogenic influence 
resulting in a marked increase in vascularity in the 
adjacent host myocardium. 
Grafted human atrial cardiomyocytes were easily 
located by their relatively increased basophilia as 
compared with the surrounding host ventricle (Fig. 
1). Little if any connective tissue was observed 
surrounding the graft and no lymphocytes or other 
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Fig, 3. In addition to fetal human atrial cells, fetal human ventricular cardiomyocytes (HI/) also survived 
transplantation. Transplanted HV cells also induced blood vessels (*) in the graft area and host ventricle 
(*), Graft areas lacked any evidence of rejection as shown by the absence of a connective tissue capsule 
(an'ow) and lymphocytes. (Hematoxylin and eosin stain; final magnification ×400.) 
immune System cell types were observable with a 
light microscope. This was clearly evident at higher 
magnification (Fig. 2). In addition to a lack of 
encapsulation, blood vessels were observed both 
within and along the perimeter of the graft (Fig. 2). 
Injecte d human fetal ventricular cardiomyocytes 
also survived and thrived after intraventricular in- 
jection (Fig. 3). At this higher magnification, it is 
once agai~ clearly evident that there is a lack of 
encapsulation, an absence of lymphocyte infiltra- 
tion, and induction of blood vessels both within and 
surrounding the graft. 
AT-1 cells, which were also injected into he ventri- 
des of host pigs, were similar in appearance to the 
human fetal cardiomyocytes. Using electron micros- 
copy, we have been able to identify nascent junctional 
contacts between host ventricular cardiomyocytes and 
transplanted AT-1 cells (Figs. 4 and 5). It is hoped that 
electron micrographic studies in progress will demon- 
strate similar junctions in the fetal human studies. 
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Fig. 4. In studies in which AT-1 cells were injected into host adult pig left ventricles (PV), clear evidence 
indicated that injected cardiomyocytes could form nascent adherent junctions (arrow) with the host 
cardiomyocytes. (Transmission electron micrograph; ×9000.) 
Fig. 5. An enlargement of the area shown in Fig. 4 demonstrating the adherent or nascent intercalated 
disc (arrow) between an adult pig left ventricular cardiomyocyte (PV) and an injected AT-1 cell. (×33,300.) 
Discussion 
To understand the obstacles to success in cardiac 
cellular transplantation, one must first understand 
the functional characteristics of the mammalian 
cardiac muscle cell. Unlike skeletal muscles cells, 
the mammalian cardiac muscle cell cannot regener- 
ate. A full understanding of mechanisms that con- 
trol the myocyte cell cycle might allow us to design 
manipulations or procedures that could initiate re- 
pair or regeneration of the adult myocardium after 
injury. This strategy could involve transplantation f 
pluripotent cardiomyocytes into the intact heart 
muscle or induction of a reversion of cardiac mus- 
cles cells in the intact heart to their biochemical 
state during early fetal growth when they were 
actively dividing and proliferating. 
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In the rat, at approximately day 17 to 20 of 
postnatal development, hyperplastic growth ceases 
for the life of the animal. 11 From that time on the 
increase in the muscle mass of the heart is due 
exclusively to hypertrophy ofpreexisting cells. It has 
been estimated that this hypertrophy may be an 
increase of more than tenfold in volume to form the 
adult myocyte. The efforts to develop a cell system 
that can be used to study cardiac muscle cell cycles 
advanced significantly when it was reported that the 
large T-antigen of the SV40 virus under control of 
the atrial natriuretic factor promoter induced large 
tumors composed of dividing myocytes in the right 
atria of transgeneic mice. 12 A tumor line was subse- 
quently developed from these mice (AT-l), which 
was shown to be actively synthesizing deoxyribonu- 
cleic acid and dividing in culture. Several days after 
being plated, these cultured AT-1 tumor cells 
formed a synchronously contracting monolayer. As 
demonstrated by cine electron microscopy, as the 
cells divided they would pull away from adjacent 
myocytes, cease beating, and progress through mi- 
tosis. Subsequently he daughter cells would resume 
beating shortly after division. 13 More recently, trans- 
geneic mice have been generated that express the 
SV40 T-antigen in both atrial and ventricular car- 
diac myocytes. Myocytes from these transgeneic 
tumors were able to proliferate in culture while 
retaining the ability to beat spontaneously. The 
significance of these collective studies is their dem- 
onstration that the differentiated a ult cardiac mus- 
cle cell from both the ventricle and the atrium can 
be stimulated to divide without the loss of their 
highly differentiated state. To further assess the 
capability :to successfully perform cellular transplan- 
tation, we undertook our series of experiments in
adult swine, using a variety of developed cell lines, 
fetal swine cardiomyocytes, adult rat atrial and 
ventricular cardiomyocytes, and finally human fetal 
myoblasts. 
Additionally, the results demonstrate hat it is 
possible to successfully transplant human cardiac 
muscle cells and myoblasts into immunosuppressed 
adult animals. Transplanted AT-1 cells and human 
fetal atrial and ventricular cells may increase the 
circulation in graft areas, which implies that they 
may well secrete an angiogenic factor. This increase 
in microcirculation could provide the grafted cells 
with a blood supply and also an avenue for removal 
of cellular debris associated with the primary injury. 
This angiogenesis is critical to the survival of any 
grafted cells and may ultimately be responsible for 
the repair of damaged heart muscle. Future studies 
will determine whether the use of cells that lack or 
have reduced immunogenicity, such as the fetal 
cardiac muscle cells, could greatly improve chances 
for successful grafting without he use of immuno- 
suppression. 
In related studies with tissue culture models, dual 
labeling experiments demonstrated adherence of 
transplanted cells to host cells via clearly linked 
adherence-typed junctions, labeled with anti-pan- 
cadherin. Higher magnification with electron mi- 
croscopy revealed nascent intercalated isks with 
both a structural component and communicating 
gap junctions. 14 Additional experiments are cur- 
rently underway using transmyocardial ultrasonic 
microcrystals to measure fractional thickening to 
determine if the transplanted cells can effect physi- 
ologic changes in the host myocardium. 
Development of in vivo and in vitro model sys- 
tems to study direct cardiac muscle cell transplanta- 
tion into damaged hearts will serve as an experi- 
mental tool in evaluating future approaches with 
homograft and xenograft cardiac muscle cell trans- 
plantation used for the direct repair of myocardial 
damage. Perfection of these cell transplantation 
systems will als0 provide an important tool in future 
cardiac gene therapy paradigms. The morphologic 
results we have demonstrated, combined with the 
functional observations that transplanted cells and 
cardiomyocytes contract in synchrony in co-culture, 
support the hypothesis that transplanted cardiac 
muscle cells can form functional couplings in vivo 
and can potentially repair damaged myocardium. 
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Discussion 
Dr. Eric A. Rose (New York, N.Y.). At a meeting in 
which heart volume reduction by excising myocardium or 
replacing it with inert prosthetic patches has been advo- 
cated for the surgical treatment of heart failure, I com- 
mend Dr. Van Meter and the Ochsner group for coura- 
geously pursuing the strategy of trying to improve cardiac 
function by the actual addition rather than the excision of 
living contractile tissue to the heart. 
The development of the cell lines used in this study 
required tremendous preliminary effort. This important 
study proves that the concept of myocardial cell transplan- 
tation is feasible in large animals, at least with regard to 
cell engraftment and the development of a self-sustaining 
blood supply. As a supplementary observation, we have 
observed in a comparable rodent model that functional 
mature gap junctions do develop in the transplanted cells, 
yet that in the absence of immunosuppression, 85% of the 
transplanted cells die by 30 days. Immunosuppression is 
therefore required for this type of undertaking to be 
successful at present. 
Dr. Van Meter, do you view the propagation of autol- 
ogous myocardial cells to be feasible ex vivo in the future, 
or might the strips of myocardium discarded by the 
reductionists also be a viable source of myocytes for this 
purpose? 
Dr. Van Meter. That is an intriguing question. To be 
very futuristic and talk more about science fiction 
perhaps than science, I believe that is feasible. The 
issue is whether the adult cardiomyocytes can in a sense 
be "derepressed" by adding the fetal myoblasts that 
might enable them to differentiate and replicate at the 
same time. 
Our thinking with the myoblasts i that there could be 
three possible mechanisms of their influence. Probably the 
least likely is that they actually regenerate in a number to 
make a significant physiologic difference in the heart's 
function. The second possibility is that they do exert a 
change in the milieu of the heart failure muscle and allow 
those cells to dedifferentiate, replicate, and repair them- 
selves. The final possibility is just that they produce an 
angiogenic influence. If you could harvest he patient's 
own cells and somehow influence them in co-culture with 
the myoblasts and reimplant them, then perhaps you 
could accomplish regeneration without the problem of 
immunosuppression. 
